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Abstract
Over half of all proteins are glycosylated, and alterations in glycosylation have been observed in numerous physiological
and pathological processes. Attached glycans significantly affect protein function; but, contrary to polypeptides, they are
not directly encoded by genes, and the complex processes that regulate their assembly are poorly understood. A novel
approach combining genome-wide association and high-throughput glycomics analysis of 2,705 individuals in three
population cohorts showed that common variants in the Hepatocyte Nuclear Factor 1a (HNF1a) and fucosyltransferase
genes FUT6 and FUT8 influence N-glycan levels in human plasma. We show that HNF1a and its downstream target HNF4a
regulate the expression of key fucosyltransferase and fucose biosynthesis genes. Moreover, we show that HNF1a is both
necessary and sufficient to drive the expression of these genes in hepatic cells. These results reveal a new role for HNF1a as
a master transcriptional regulator of multiple stages in the fucosylation process. This mechanism has implications for the
regulation of immunity, embryonic development, and protein folding, as well as for our understanding of the molecular
mechanisms underlying cancer, coronary heart disease, and metabolic and inflammatory disorders.
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Introduction
Glycosylation is a post-translational modification that enriches
protein complexity and function. Over half of all known proteins
are modified by covalently bound glycans, which are important for
normal physiological processes, including protein folding, degra-
dation and secretion, cell signalling, immune function and
transcription [1–4]. Configuration and composition of attached
glycans significantly change the structure and activity of
polypeptide portions of glycoproteins [5] and since this process
is not template driven, complexity of the glycoproteome is
estimated to be several orders of magnitude greater than for the
proteome itself [6]. Disregulation of glycosylation is associated
with a wide range of diseases, including cancer, diabetes,
cardiovascular, congenital, immunological and infectious disorders
[1,3,7]. Enzymes that are involved in glycosylation may therefore
be promising targets for therapy [8]. The most prominent example
of the importance of N-glycosylation is the group of rare diseases
named congenital disorders of glycosylation [9] where different
mutations in the biosynthesis pathway of N-glycans cause
significant mortality and extensive motor, immunological, diges-
tive and neurological symptoms [10,11].
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complex biological samples, our understanding of the genetic
regulation of glycosylation is currently very limited [12]. However,
recent technological advances have allowed reliable, high-
throughput quantification of N-glycans [13], which now permits
investigation of the genetic regulation and biological roles of
glycan structures and brings glycomics into line with genomics,
proteomics and metabolomics [14]. Recently we completed the
first comprehensive population study of human plasma N-glycome
which revealed variability that by far exceeds the variability of
proteins and DNA [15]. However, within a single individual
composition of plasma glycome is rather stable [16] and
environmental factors have limited impact on the majority of
glycans [17]. Specific altered glyco-phenotypes that can be
associated with specific pathologies were also identified to exist
in a population [18].
Variations in glycosylation are of great physiological signifi-
cance as alterations in glycans significantly change the structure
and function of polypeptide parts of glycoproteins [5]. A
particularly interesting element of protein glycosylation is the
addition of fucose to non-reducing ends of N-glycans. Fucose is a
relatively novel sugar in evolutionary terms with two important
structural features that distinguishes it from all other mammalian
six-carbon monosaccharides; it lacks a hydroxyl group on the
carbon at the 6-position and is the only monosaccharide that is in
the L-configuration. The conversion of GDP-mannose to GDP-
fucose is catalyzed by two enzymes (GMD and FX) that display
remarkable evolutionary conservation [19,20]. On the other hand,
the large family of genes that add fucose to proteins and lipids
(fucosyltranferases, FUTs) has a very complex evolutionary
history, including several more recent events specific to primates
[21]. In mammals, fucose-containing glycans have important roles
in blood transfusion reactions, in the selectin-mediated leukocyte-
endothelial adhesion that initiates an inflammatory response, in
host-microbe interactions, and numerous ontogenic events
[10,19]. Acute phase proteins have altered fucosylation in many
diseases [22] and changes in the levels of fucosylated glycans have
been shown to be associated with several important pathological
processes, including cancer [23].
Hepatocyte nuclear factor 1a (HNF1a) and its downstream
target HNF4a are transcription factors that regulate gene
expression in both the liver and pancreas in a tissue-specific
manner and are key regulators of metabolic genes [24]. Mutations
in the encoding genes HNF1a and HNF4a cause Maturity Onset
Diabetes of the Young (MODY) types 3 and 1 respectively [25,26].
Recently, HNF1a single nucleotide polymorphisms (SNPs) have
been associated with plasma C-reactive protein (CRP) [27], LDL
cholesterol and gamma glutamyltransferase (GGT) [28], and
coronary heart disease [29]. HNF4a variants have been associated
with ulcerative colitis [30] and with the plasma concentrations of
CRP and apolipoprotein A1 (APOA1) [31]. Currently there is
little evidence to link these transcription factors with fucose
metabolism and the upstream mechanisms regulating fucosylation
pathways are unknown.
Results
Common variants in fucosyltransferase genes affect the
relative proportions of plasma N-glycans
We performed the first systematic analysis of the genetic
regulation of individual N-glycans in plasma from 2,705
individuals in three population cohorts, from Croatia and
Scotland, which have previously been characterized in great detail
[32]. Desialylated 2AB-labelled human plasma N-glycans were
separated into 13 structurally related groups of glycans, referred to
as DG1–DG13 (see Table S1 for a list of specific glycans found
within each DG group) [13]. The concentration of plasma N-
glycans measured in each of these groups was then expressed as a
proportion of the total plasma N-glycome to obtain 13 quantitative
variables in each examinee. All N-glycans contain two core N-
acetylglucosamine (GlcNAc) residues, to which a ‘‘core’’ fucose
can be a1,6-linked to the inner GlcNAc, which is directly linked to
an asparagine residue on the protein. Additional fucose residues
can be transferred to different positions on antennas that have
been added to the core glycan structure (Table S1). Two further
traits were derived from the original variables to calculate the
percentage of glycan structures containing core (FUC-C) or
antennary (FUC-A) fucose, yielding a total of 15 glycan traits for
analysis.
We conducted a meta-analysis of genome-wide association
study (GWAS) data for the fifteen plasma N-glycan traits measured
in three population-based cohorts, CROATIA-VIS (n=924),
CROATIA-KORCULA (n=898) and ORCADES (n=737).
Additive SNP effects were tested in each cohort independently
and then combined in an inverse-variance weighted meta-analysis.
The genome-wide significance threshold for the meta-analysis was
set at 5610
208.
Genome-wide significant associations were found for DG1,
DG6, DG7, DG9, DG11, as well as FUC-A (Table 1; Figure 1 and
Figure 2). Association profiles for DG1, DG7, and DG9 are
represented in their genomic context in Figure 1 for the associated
region. Quantile–quantile plots for each association were consis-
tent with an excess of true genetic associations, with modest
genomic control inflation for each population (inflation factor
,1.04 for all traits and each population as well as the meta-
analysis), suggesting that the observed results were not due to
population stratification (Figure 2A–2C).
Fifteen SNPs located in the region encompassing the fucosyl-
transferase 8 gene (FUT8, Entrez GeneID: 2530) on chromosome
14 were significantly associated with plasma concentrations of
desialylated glycan (DG) 1, the most significant being rs7159888
(p=3.46610
218) located 59 of the gene. FUT8 was also associated
with DG6, however for this trait only one SNP, rs10483776,
reached genome-wide significance (p=9.58610
209). All SNPs
significantly associated with DG1 levels were in high LD (r
2.0.5)
and located between two recombination hotspots, while no
associations were found with SNPs located outside these
boundaries nor with other genes located within this association
Author Summary
By combining recently developed high-throughput glycan
analysis with genome-wide association study, we per-
formed the first comprehensive analysis of common
genetic polymorphisms that affect protein glycosylation.
Over half of all proteins are glycosylated; but, due to
difficulties in glycan analysis and the absence of a genetic
template for their synthesis, knowledge about the
complex processes that regulate glycan assembly is still
limited. We demonstrated that HNF1a regulates the
expression of key fucosyltransferase and fucose biosyn-
thesis genes and acts as a master regulator of plasma
protein fucosylation. Proper protein fucosylation is essen-
tial in numerous processes including inflammation, cancer,
and coronary heart disease, thus the identification of a
master regulator of plasma protein fucosylation has
important implications for understanding both normal
biological functions and disease processes.
HNF1a Is a Master Regulator of Fucosylation
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was 20.2617 (s.e. 0.0301) for DG1 in the meta-analysis of the 3
populations studied (standard deviation units, after adjustment for
sex and age; Figure 2D). All significant SNPs in this region had a
similar effect size (absolute value of the range: 0.1828–0.3251),
accounting for between 1 and 6 percent of the trait variance after
adjustment for age and sex. The effect of rs7159888 on DG1 was
consistent across populations with similar amplitude and direction
of effect (Figure 2D) with the effect for each population plotted
separately along with the pooled effect. Haplotype analysis found
that a single SNP model performed better than the 3- or 5-SNP
haplotype model in every population.
A single SNP located on chromosome 19, rs3760776, was
associated with DG7, DG9, DG12 and FUC-A (p=3.42610
212,
p=3.51610
217, p=9.44610
210, p=1.41610
212). This SNP is
located at the 59 end of the fucosyltranferase 6 gene (FUT6, Entrez
GeneID: 2528). The association interval for this SNP contains the
NRTN, FUT6 and FUT3 genes (see Figure 1C), of which FUT6
and FUT3 are both biologically plausible candidates to explain the
observed associations. The effect size of the G allele of rs3760776
is 0.3387 (s.e. 0.0487) for DG7 (standard deviation units, after
adjustment for significant covariates: sex, age and fibrinogen); and
0.4104 (s.e. 0.0487), 0.2974 (s.e. 0.0486), and 0.3446 (s.e. 0.0486)
for DG9, DG12 and FUC-A respectively (standard deviation units,
after adjustment for age and fibrinogen). These effects account for
2% (DG7), 3% (DG9), 2% (DG12) and 2% (FUC-A) of the trait
variance. A forest plot of the effect size of rs3760776 in each
population and the meta for DG7 is presented in Figure 2F.
Haplotype analysis suggested that a 5-SNP haplotype across this
region has a stronger effect on these glycan levels than a single
SNP model. Another fucosyltransferase gene (FUT3) is also within
the region, so the causal variant(s) may affect one or both of these
genes. The best 5-SNP haplotype contained rs3760776 and
encompassed FUT6 but not FUT3 in every population and for
every glycan group tested which suggests that the association is
with FUT6, not FUT3.
The glycan structures which were significantly associated with
genetic variants in the FUT6 and FUT8 genes are summarised in
Table 1. Glycan group DG1 consists of a single structure
GlcNAc2Man3GlcNAc2 that is known to be a substrate for the
a1-6-fucosyltransferase (FUT8) (Table S1) [15,33]. Group DG6
contains three glycan structures, two of which are core fucosylated
so the results are consistent with the known biological role of
FUT8. In contrast, groups DG7, DG9 and DG12 include glycans
containing antennary fucose while FUC-A was derived as an
overall measure of antennary fucosylation. FUT6 encodes the
enzyme fucosyltransferase VI which was reported to be the key
enzyme responsible for the a3-fucosylation of plasma proteins [34].
The association of FUT8 and FUT6 genes with N-glycan
structures containing core and antennary fucosylation is supported
by their known biological functions [35] and the fact that they
were identified in this study is an effective proof of principle that
HPLC measured glycan levels can be used to identify genes that
regulate protein glycosylation.
Novel association of HNF1a with N-glycans
Two SNPs on chromosome 12, rs7953249 and rs735396,
showed genome-wide significant associations with DG7
(p=1.97610
208, p=1.75610
208). The latter SNP was also
associated with DG11 (p=4.44610
208), with an effect in the
opposite direction, and was close to genome-wide significance with
DG9 (Table S2). Both SNPs are located in the HNF1a (Entrez
GeneID: 6927) gene region: rs7953249 is found 13 kb 59 to the
gene and rs735396 is in intron 9. Two other genes are found
between the recombination hotspots that comprise the boundaries
of the association interval, C12orf43 and OASL (Figure 1B).
However, none of the most significantly associated SNPs are
located in these genes and all SNPs with suggestive p-values
(p,1610
205) are located within HNF1a (Table S2). The effect size
of the G allele of rs735396 is 20.1767 (standard deviation units,
after adjustment for sex, age and fibrinogen; s.e. 0.0314) for DG7,
which only contains glycans with antennary fucose, and in the
opposite direction (0.1699 standard deviation units, after adjust-
ment for age and fibrinogen; s.e. 0.0310) for DG11, which has no
antennary fucose (Table 1). All significant SNPs in this region had
a similar effect size (absolute value of the range: 0.1396–0.1767),
representing 1–3% of the trait variance. Figure 2E shows the effect
size for rs735396 with DG7 for each population separately and the
pooled meta-analysis. Comparison of models including rs7953249
and rs735396 separately and combined suggests that the causal
variant is located between these two SNPs. This was confirmed by
analysis of imputed data based on HapMap release 2 with the
most significant SNPs located across intron 1 of HNF1a.
Table 1. Genetic markers associated with plasma N-glycan levels.
Trait
Fucosylation
status Chr SNP
Meta-analysis
P-value
Meta-
analysis
sample size
Associated
interval size, kb
(no. of genes in
interval)
Genes within
associated
interval
Major allele,
minor allele
(MAF)
Effect size for
minor allele
(s.e.)
(z-score units)*
DG1 NF 14q23.3 rs7159888 3.46610
218 2,441 650 (1) FUT8 G, A (0.44) 0.26 (0.03)
DG6 CF 14q23.3 rs10483776 9.58610
209 2,332 650 (1) FUT8 A, G (0.21) 20.22 (0.04)
DG7 AF 12q24.31 rs7953249 1.97610
208 2,321 118 (3) HNF1A-C12orf43-OASL A, G (0.45) 20.17 (0.03)
DG7 AF 19p13.3 rs3760776 3.42610
212 2,320 54 (3) NRTN-FUT6-FUT3 G, A (0.11) 20.34 (0.05)
DG9 AF, CF 19p13.3 rs3760776 3.51610
217 2,333 54 (3) NRTN-FUT6-FUT3 G, A (0.11) 20.41 (0.05)
DG11 NF/CF, AF 12q24.31 rs735396 4.44610
208 2,333 118 (3) HNF1A-C12orf43-OASL A, G (0.38) 0.17 (0.03)
DG12 AF 19p13.3 rs3760776 9.44610
210 2,330 54 (3) NRTN-FUT6-FUT3 G, A (0.11) 20.30 (0.05)
FUCA AF 19p13.3 rs3760776 1.41610
212 2,321 54 (3) NRTN-FUT6-FUT3 G, A (0.11) 20.34 (0.05)
*Effect size shown is the b-coefficient, which represents change in glycan levels measured in standard deviation units (after adjustment for covariates) per copy of the
allele modelled. NF, non-fucosylated; CF, core fucosylated; AF, antennary fucosylated; See also Tables S1 and S2.
doi:10.1371/journal.pgen.1001256.t001
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(1) regulation of GDP-fucose biosynthesis
The shared characteristic of all glycan groups that showed
association with HNF1a SNPs was the presence or absence of
antennary fucose (Table S2). We hypothesised that HNF1a
transcriptionally regulates the expression of genes involved in the
separates steps of fucosylation. This is supported by the fact that a
functionally related transcription factor, HNF4a was previously
shown to bind the regulatory elements of the GDP-mannose-4,6-
dehydratase (GMDS) gene in a genome-wide ChIP-ChIP. GMDS
is involved in the de novo pathway of L-fucose synthesis to produce
GDP-fucose, the substrate used by both core and antennary
fucosyltransferases to N-glycosylated proteins [24]. Moreover,
HNF4a directly regulates the expression of the hepatic fucosyl-
transferase VI gene (FUT6) [36]. Therefore, we tested whether
HNF1a and/or HNF4a might regulate other genes involved in
GDP-fucose biosynthesis. To this end, HNF1a and HNF4a were
transiently knocked-down in liver and pancreatic cell lines using
RNA interference. Both HNF1a and HNF4a expression levels
decreased upon knockdown of either of them in hepatocytes
(Figure 3A). In pancreatic cells, HNF1a knockdown up-regulates
HNF4a expression but the reverse is not true (Figure S1). This
confirms the differential regulation of gene expression downstream
of HNFs in liver vis-a-vis pancreas [28,37]. It also corroborated
recent findings in murine Hnf1a hetrozygote pancreas, where the
levels of Hnf4a mRNA increase [38].
As a positive control, the expression of FUT6, a known target of
HNF4a in hepatocytes, was first analysed. The ablation of the
HNF4a transcript abolished the expression of FUT6 in HepG2
cells confirming that the knockdown was effective. Surprisingly,
knockdown of HNF1a resulted in 50% reduction in FUT6
transcript levels suggesting that HNF1a also regulate FUT6
expression in HepG2. This experiment suggested that our
hypothesis may potentially explain and provide a direct link
between HNF1a and the fucosylation genes. Therefore, we
focused on the genes responsible for fucose biosynthesis, a rate
limiting step in protein fucosylation. To this end, we analysed the
expression of GMDS and L-Fucokinase which regulate de novo and
salvage pathways of fucose synthesis, respectively. In HepG2 liver
cells, HNF1a and HNF4a knockdown resulted in dramatic down-
regulation in the expression of GMDS (91 and 77%, respectively)
and L-Fucokinase (92 and 98%, respectively) (Figure 3B). In the
pancreatic Panc1 cell lines, HNF4a RNAi resulted in a 70%
decrease in GMDS and L-Fucokinase transcript levels (Figure 1).
However, HNF1a RNAi led to a 90% reduction in GMDS
transcript levels but did not affect L-Fucokinase mRNA abundance
(Figure 1). This suggests that HNF1a regulates de novo synthesis of
d-fucose in both cell lines tested (liver and pancreas), but only the
salvage pathway in the liver cell line tested. HNF4a, on the other
hand, regulates both pathways in both cell types tested.
We therefore focused on HNF1a direct transcriptional
regulation of HNF4a, GMDS and L-Fucokinase in HepG2 cells. In
order to investigate the latter, we performed a bioinformatics
analysis to delineate in silico HNF1a and HNF4a binding sites.
First, we assessed the conservation of regulatory elements (at the 59
and 39 end) between human and other primates as described
previously [39]. It was recently shown the sites are not conserved
between primates and rodents [40]. Second, the conserved regions
were then mined for potential sites using ECR browser and the
TRANSFAC database [41]. Finally, the potential sites were
analysed manually to ascertain the likely binding sites based on
homology to HNF1a and HNF4a consensus binding sites mined
using genome-wide ChIP analyses [40,42]. This limited our
analysis to 5 sites (primer pairs P16 to P20, Figure 3C) in the
GMDS promoter, 3 sites in the promoter (primer pairs P21 to P23,
Figure 3D) as well as 2 sites at the 39end (primer pairs P24 and
P25, Figure 3D) of the L-Fucokinase gene and 3 sites in the
promoter (primer pairs P34 to P36, Figure 3D) as well as a single
site at the 39 end (primer pair P37) of the HNF4a gene. The primer
pairs are less than 1Kbps away from each other and some
contained both HNF1a and HNF4a binding sites (or half sites)
within the 200bps amplifiable regions.
Using these primer pairs, we performed chromatin immuno-
precipitation (ChIP) assays to delineate the occupancy of these sites
by HNF1a, HNF4a or both proteins as described earlier [43,44].
In HepG2, both HNF1a and HNF4a bind the promoters of
GMDS (P17, Figure 3C), L-Fucokinase (P22 although the two factors
cannot be re-precipitated, Figure 3D) and HNF4a (P36, Figure 3E).
Also, we show binding of HNF1a and HNF4a at the 39UTR of L-
Fucokinase as well as HNF4a binds the 39UTR of HNF4a
(Figure 3D and 3E, respectively). The interactions of these
proteins is not affected by shearing as the primers acts as genomic
controls for each other and no signal above background was
apparent in the IgG isotype control antibody. Together, the data
suggests a complex network of interactions between HNF4a and
HNF1a to regulate fucose biosynthesis gene expression and point
to a novel and an unappreciated role for HNF1a in regulating the
two genes studied (GMDS and L-fucokinase). We further investigated
the role of HNF1a in regulating the activity of the promoter
regions bound by HNF factors (i.e. regions amplified by primer
pairs P17, P22 and P37). We cloned these fragments into luciferase
expressing vector (Promega’s pGL4-basic) and assayed for reporter
activity in two systems to delineate whether HNF1a is necessary to
drive reporter expression (RNAi in HepG2 cells) and sufficient
(expression of HNF1a in HEK293 cells that do not express
endogenous HNF1a). Knockdown of HNF1a leads to a downreg-
ulation in the activity of both GMDS (5 fold reduction) and L-
Fucokinase (2 fold reduction) promoter regions. Conversely, HNF1a
overexpression leads to the induction of the luciferase activity in
reporters driven by the two promoter regions. Put together, the
expression data combined with the ChIP analysis and the reporter
activity results strongly support a direct role for HNF1a in
regulating the two key genes GMDS and L-Fucokinase that are
responsible for de novo and salvage pathway of fucose synthesis.
HNF1a regulates multiple stages in protein fucosylation:
(2) transcriptional regulation of core and antennary
fucosyltransferases
After confirming the role of HNF1a in the biosynthesis of GDP-
fucose, we analysed the role of HNF1a and HNF4a in the
regulation of the expression of fucosyltransferase (FUT) genes
(FUT3-11) in HepG2 and Panc1 cell lines to assess whether these
hepatic factors regulate other stages of protein fucosylation. In
HepG2 cells, HNF1a knockdown down-regulated the expression
Figure 1. Significance plots. Significance plots for regions of interest from the meta-analysis of (a) DG1, (b) DG7 and (c) DG9. A region around the
most significant genotyped SNP (represented by a red diamond) is displayed with the –log10 of the association p-values plotted against chromosome
position. The degree of linkage disequilibrium between the most significant SNP and any SNP tested is indicated by a gradient of red shading.
Recombination rate is displayed by a blue line with scale on the right-hand axis. Characterized genes in the region are represented with an arrow
(showing the direction of transcription). The accompanying association interval as defined in the methods is marked by vertical red dotted lines.
doi:10.1371/journal.pgen.1001256.g001
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induced upon the loss of HNF1a (Figure 4C). HNF4a knockdown
led to a statistically significant downregulation of FUT3, FUT5,
FUT6, FUT10, FUT11 but not FUT7 or FUT9 (Figure 4A and 4B).
Conversely, FUT8 expression levels increased 10 fold upon the loss
of HNF4a ((Figure 4C). FUT4 was not expressed in HepG2 cells
confirming earlier studies [45]. In the pancreas, all FUT genes were
down-regulated (Figure 2) pointing to a key role for HNF1a in the
regulation of fucosylation in the pancreas. Knockdown of HNF4a in
liver cells reduced the expression of all FUT genes analysed except
FUT7 or FUT9, but to a lesser extent than HNF1a knockdown
(Figure 4A and 4B), however, FUT8 was again up-regulated
(Figure 4A and 4B). The data supports a wider effect of HNF1a on
the expression of the 8 fucosyltransferase genes compared to
HNF4a. The data also suggests that HNF1a and HNF4a
downregulate FUT8, which adds fucose to the core glycan, in
contrast to all other FUTs that add fucose to the antennary arms of
glycans [33]. We observed a rather high correlation between
concentrations of antennary and core fucose in our population
samples (r=0.574, p=4.01610
285), indicating that the availability
of the common substrate of both core and antennary FUTs, GDP-
fucose, is a rate-limiting factor in protein fucosylation. It therefore
appears that HNF1a not only enhances the activity of antennary
FUTs but also, by down-regulating FUT8, increases the amount of
GDP-fucose available for antennary fucosylation.
FUT3, FUT6 and FUT5 were the only FUTs to be highly
repressed (more than 3-fold) upon the loss of both HNF1a and
HNF4a in liver cells (Figure 4A), suggesting a co-regulation of the
three genes. In pancreatic cells, FUT3 and FUT6, but not FUT5
followed the same dynamics (Figure 2). FUT3 and FUT6
expression was not repressed upon HNF4a loss (Figure 2). This
could be explained by a differential role for HNF4a in regulating
FUT5 but not FUT3 or FUT6. These data suggest that HNF1a is
the major regulator of the fucosylation pathway in both liver and
pancreatic cell lines. While HNF4a also regulates the expression of
these genes, its role is probably secondary to HNF1a. However,
none of the genes studied here have previously been shown to be
regulated in vivo by HNFs. Only the GMDS promoter has
previously been shown to be chromatin immunoprecipitated with
HNF4a antibody [28].
Bioinformatic analysis showed that FUT3, FUT5 and FUT6 are
clustered in one locus in the human genome (see and Figure S3)
[39]. This also corroborated our findings that FUT3, FUT5 and
FUT6 are co-regulated downstream of HNF4a and HNF1a
(Figure 4A). However, the FUT3/5/6 cluster was neither syntenic
nor conserved in the mouse genome. We therefore focused on
primate conservation only.
The promoter, intergenic and 39 regulatory element conserved
regions were analysed for HNF binding sites as detailed above for
GMDS and L-Fucokinase. This analysis identified a limited number
of sites in regulatory regions of FUT3, FUT5, FUT6, and FUT10.
It did not identify any binding sites in silico in the FUT11 promoter,
but a highly conserved long range enhancer was found within the
ADK gene, that is 650 kb upstream and rich in HNF binding sites.
We were unable to detect any HNF binding sequences within the
FUT8 regulatory elements analysed.
Using ChIP, the binding of HNF1a and HNF4a to the putative
response elements identified in silico was analysed. ChIP analysis
showed that HNF1a and HNF4a bound multiple sequences
within the predicted regulatory regions of multiple FUT genes,
including FUT3, FUT5, FUT6, FUT10, FUT11 (Figure 4D–4I).
HNF4a, and not HNF1a, bound the promoter of FUT5 (P13 and
P15, Figure 4G). The unique binding of HNF4a to the promoter
of FUT5 corroborated our findings that knockdown of HNF4a in
pancreatic PANC1cells abolished the expression of FUT5 but not
FUT3 or FUT6 (Figure 2).
Using re-precipitation (reChIP), we confirmed that both HNF
transcription factors bound (i) the promoters of FUT3, FUT6 and
FUT10 (Figure 4E, 4F, 4D, and 4I respectively); (ii) 39UTRs of
FUT6 (Figure 4D); and (iii) the long range enhancer 650 kb
upstream of FUT11 (Figure 4H). This shows that HNF1a and
HNF4a are potential regulators of the expression of these genes
in vivo.
Discussion
By performing the first genome-wide association analysis
(GWAS) of protein glycosylation we have taken the first steps
towards the mapping of the complex network of genes that
regulate protein N-glycosylation. We also identified common
variants in three genes which exert a relatively strong influence on
N-glycans in plasma (1–6% of variance explained). Importantly, all
of the identified genes (FUT6, FUT8 and HNF1a) are involved in
fucosylation, indicating that the addition of this unusual sugar may
be a rate-limiting step in N-glycan synthesis. A gene encoding the
transcription factor HNF1a, with previously unknown biological
links to glycosylation, is shown to be strongly associated with the
relative proportions of plasma N-glycans. The possible function(s)
of HNF1a are a focus of intense current interest following its
recently reported associations in GWAS with plasma C-reactive
protein (CRP) [27], gamma-glutamyl transferase (GGT) [28],
LDL cholesterol and apolipoprotein [29,31] and coronary artery
disease [29,46]. Our analysis of gene knockdowns (RNAi) showed
that HNF1a is an upstream regulator of several key genes involved
in different stages of the fucosylation pathway. We have
demonstrated that HNF1a binds the promoters in vivo, and is
necessary and sufficient for the in vitro expression, of two genes,
fucokinase and GMDS, required for de novo and salvage pathways of
fucose synthesis, respectively (Figure 5C). Fucose synthesis is the
rate limiting step for fucosylation in eukaryotes and prokaryotes
[35] and, by up-regulating its synthesis, HNF1a increases the
availability of fucose to the glycosylation machinery. In addition,
HNF1a directly regulates the expression of several fucosyltransfer-
ase (FUT) genes (Figure 5D). Our results also demonstrate that
HNF1a reciprocally regulates core versus antennary fucosylation;
while activating FUTs involved in antennary fucosylation, HNF1a
represses FUT8, which adds fucose to the core-GlcNAc. In
this way, HNF1a decreases the consumption of GDP-fucose for
core-fucosylation, and further increases the pool of fucose available
for antennary fucosylation.
Having shown this novel regulation of fucosylation genes, we
scanned earlier genome wide studies for HNF factors to identify
whether these genes were picked up. In fact, other genome wide
Figure 2. Quantile–quantile plots and forest plots. Quantile-quantile plots for test statistics (a–c) and forest plots of the most significant SNPs
(d–f) from the meta-analysis of DG1, DG7, and DG9. 2Log10 of the association p-values are plotted against 2log10 of the expected p-value under the
null hypothesis of no association for the meta-analysis. The effect size estimates for each individual population and the meta-analysis are shown
along with their standard errors. The effect size presented is the b-coefficient, which represents a change in glycan levels measured in standard
deviation units (adjusted for covariates) per copy of the allele modelled. The mean effect size estimates are represented by a square for individual
cohorts where the size is proportional to its contribution to the pooled effect size.
doi:10.1371/journal.pgen.1001256.g002
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PLoS Genetics | www.plosgenetics.org 8 December 2010 | Volume 6 | Issue 12 | e1001256studies support our findings. Boyd et al (2009) mapped HNF4a
binding to both FUT2 and FUT5 in intestinal epithelial cells [42].
A genome wide prediction study for HNF4a functional binding
sites identified FUT6, FUT5, FUT9, GMDS and FUT12 as
functional targets [47].
We hypothesize that the role of HNF1a and its transcriptional
co-factor HNF4a in the regulation of fucosylation is an essential
part of mounting an acute phase response to infection in humans.
Antennary fucosylation of their glycoprotein ligands is needed for
binding of E-, L- and P-selectins to their target cells and the
initiation of inflammation [48]. The decrease in fucosylation in the
rare Leukocyte Adhesion Deficiency II (LAD II) impairs
neutrophil function, which can be restored by oral administration
of fucose [49]. Recently, we have reported moderate correlations
between fucosylated plasma N-glycans and components of the
acute phase response [15], which are also highly glycosylated and
have high content of antennary-fucose [50]. Mounting a successful
acute-phase response requires a rapid increase in the concentra-
tion of acute-phase proteins and this in turn is dependent on their
efficient fucosylation. Our results indicate that fucosylation is a
rate-limiting step in plasma protein glycosylation, and by both
increasing de novo and salvage synthesis of GDP-fucose, up-
regulation of antennary fucosyltransferases and down-regulation of
core-fucosyltransferase, HNF1a appears to be a master regulator
of this process. Variants in HNF1a and HNF4a genes were
previously reported to be associated with concentrations of acute
phase proteins in human plasma [24,27]. Plasma protein
fucosylation plays an important role in inflammation [22] and
the central role of HNF1a in the regulation of multiple genes
involved in fucosylation may be the molecular mechanism behind
the reported association between common variants in HNF1a and
inflammatory markers (such as CRP) as well as several diseases in
which inflammation plays a key pathogenic role (such as coronary
artery disease, inflammatory bowel disease and cancer).
Materials and Methods
Study populations and genotyping
All three populations recruited adult individuals within a
community irrespective of any specific phenotype. The CROA-
TIA-VIS and CROATIA-KORCULA studies are both cohorts
from the Croatian Dalmatian islands recruited in 2003–2004 and
2007 respectively. The ORCADES study is ongoing with
participants recruited from the Orkney islands in Scotland.
Fasting blood samples were collected, biochemical and physiolog-
ical measurements taken and questionnaires of medical history as
well as lifestyle and environmental exposures collected following
similar protocols.
The CROATIA-VIS study includes 1008 Croatians, aged 18–
93 years, who were recruited from the villages of Vis and Komiza
on the Dalmatian island of Vis during 2003 and 2004 within a
larger genetic epidemiology program [32].
The CROATIA-KORCULA study includes 969 Croatians
between the ages of 18 and 98 [32]. The field work was performed
in 2007 in the eastern part of the island, targeting healthy
volunteers from the town of Korc ˇula and the villages of
Lumbarda, Z ˇrnovo and Rac ˇis ˇc ´e.
The Orkney Complex Disease Study (ORCADES) is an
ongoing study in the isolated Scottish archipelago of Orkney
[32]. Data for participants aged 18 to 100 years, from a subgroup
of ten islands, were used for this analysis.
DNA samples were genotyped according to the manufacturer’s
instructions on Illumina Infinium SNP bead microarrays (Hu-
manHap300v1 for the CROATIA-VIS cohort, HumanHap300v2
for the ORCADES cohort and HumanCNV370v1 for the
CROATIA-KORCULA cohort). Genotypes were determined
using Illumina BeadStudio software. Genotyping was successfully
completed on 991 individuals from CROATIA-VIS, 953 from
CROATIA-KORCULA and 761 from ORCADES.
Ethics statement
All studies conformed to the ethical guidelines of the 1975
Declaration of Helsinki and were approved by appropriate ethics
boards with all respondents signing informed consent prior to
participation.
Glycan release and labelling
The N-glycans from plasma sample (5 ml) proteins were released
and labelled with 2-aminobenzamide (LudgerTag 2-AB labelling
kit Ludger Ltd., Abingdon, UK) as described previously [13].
Labelled glycans were dried in a vacuum centrifuge and
redissolved in known volume of water for further analysis.
Sialidase digestion
After initial HPLC quantification sialidase digestion was
performed to improve measurement precision. Aliquots of the 2-
AB-labeled glycan pool were dried down in 200-ml microcentrifuge
tubes. To these, the following was added: 1 ml of 500 mM sodium
acetate incubation buffer (pH 5.5), 1 ml (0.005 units) of ABS,
Arthrobacter ureafaciens sialidase (releases a2–3, 6, 8 sialic acid,
Prozyme) and H2O to make up to 10 ml. This was incubated
overnight (16–18 h) at 37uC and then passed through a
Micropure-EZ enzyme remover (Millipore, Billerica, MA, USA)
before applying to the HPLC.
Hydrophilic interaction high-performance liquid
chromatography (HILIC)
Released glycans were subjected to hydrophilic interaction high
performance liquid chromatography (HILIC) on a 25064.6 mm
i.d. 5 mm particle packed TSKgel Amide 80 column (Tosoh
Bioscience, Stuttgart, Germany) at 30uC with 50 mM formic acid
adjusted to pH 4.4 with ammonia solution as solvent A and
acetonitrile as solvent B. 60 min runs were on a 2795 Alliance
separations module (Waters, Milford, MA). HPLCs were equipped
with a Waters temperature control module and a Waters 2475
fluorescence detector set with excitation and emission wavelengths
of 330 and 420 nm, respectively. The system was calibrated using
Figure 3. HNF1a is major regulator of fucose synthesis pathway genes. A). Real time PCR for HNF1a, HNF4a and FUT6 RNAs after HNF1a and
HNF4a RNA interference (RNAi) in HepG2 cells. B). Real time PCR for GMDS and L-Fucokinase transcripts after HNF1a and HNF4a RNA interference
(RNAi) in HepG2 cells. Expression levels were compared to GAPDH transcripts. All experiments were performed in triplicate. C). Chromatin
immunoprecipitation (ChIP) analysis of regions as determined by the indicated primer sets for the GMDS promoter. D). ChIP analysis of regions as
determined by the indicated primer sets for the L-Fucokinase promoter and 39 UTRs. E). ChIP analysis of regions as determined by the indicated
primer sets for the HNF4a promoter and 39 UTRs. F). Reporter activity of the control FUT6 promoter upon HNF1a RNAi in HepG2 cells or pcDNA3-
HNF1a expression in HEK293 cells. G). Reporter activity of the GMDS and L-Fucokinase promoters upon HNF1a RNAi in HepG2 cells or pcDNA3-HNF1a
expression in HEK293 cells. Abbreviations: HNF: Hepatocyte nuclear factor; RNAi: RNA interference, GMDS: GDP-mannose 4,6-dehydratase; L-Fuc: L-
Fucokinase; FUT: Fucosyltranferase. 39UTR: 39 un-translated region. reChIP: re-precipitation (or sequential) ChIP. See also Figure S2 for gene expression
results in PANC1 cell line.
doi:10.1371/journal.pgen.1001256.g003
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PLoS Genetics | www.plosgenetics.org 9 December 2010 | Volume 6 | Issue 12 | e1001256Figure 4. HNF1a is major regulator of the fucosyltransferase genes. Real time PCR for FUT3, FUT5 and FUT6 RNAs (A); FUT7, FUT9, FUT10 and
FUT11 (B); FUT8 (C) after HNF1a and HNF4a RNA interference (RNAi) in HepG2 cells. H) analyses show that Hnf1a (HNF1) and Hnf4a (HNF4) bind
predicted regulatory elements for key fucosylation genes in liver cells. D), E), F), G), H) and I) Binding of HNF1a and HNF4a to predicted regulatory
elements of the FUT3, FUT5, FUT6, FUT10 and FUT11. Abbreviations: the gene names are detailed in Figure 1; P1–P37: Primer sets 1 to 37; 39UTR: 39 un-
translated region. reChIP: re-precipitation (or sequential) ChIP.
doi:10.1371/journal.pgen.1001256.g004
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PLoS Genetics | www.plosgenetics.org 10 December 2010 | Volume 6 | Issue 12 | e1001256Figure 5. HNF1a is at the heart of fucosylation regulation. A). Diagram showing HNF1a and HNF4a regulation of pathways involved in fucose
synthesis. B). Pathways of core (tri-mannosyl-chitobiose) and antennary fucosylation and their proposed regulation by the transcription factors Hnf1a
and Hnf4a, encoded by the HNF1a and HNF4a genes respectively. Red arrows indicate genes that are targets of Hnf1a/Hnf4a. Solid lines show direct
regulation and dashed lines show indirect regulation of the FUT genes shown. Genes shown in blue depict GWAS identified genes (HNF1a, FUT6 and
FUT8). Abbreviations: Neu5Ac, N-Acetylneuraminic (sialic) acid; GlcNAc, N-acetylglucosamine; Man, mannose; Gal, galactose; poly-LacNAc,
Galb1,4GlcNAc (LacNAc) antennary chains; Asn, asparagine residue on glycosylated protein.
doi:10.1371/journal.pgen.1001256.g005
HNF1a Is a Master Regulator of Fucosylation
PLoS Genetics | www.plosgenetics.org 11 December 2010 | Volume 6 | Issue 12 | e1001256an external standard of hydrolyzed and 2-AB-labeled glucose
oligomerase from which the retention times for the individual
glycans were converted to glucose units (GU) [51]. Glycans were
analyzed on the basis of their elution positions and measured in
glucose units then compared to reference values in NIBRT’s
‘‘GlycoBase v3.0 ’’ database available at http://glycobase.nibrt.ie)
for structure assignment [52].
HPLC analysis was performed partly in the National Institute
for Biotechnology and Training (NIBRT) in Dublin, Ireland, and
partly in the Glycobiology laboratory of Genos Ltd in Zagreb,
Croatia. Both laboratories used the same columns and separation
conditions. Duplicate analysis of a number of samples was
performed and confirmed full reproducibility of the analytical
results both within and between laboratories.
Glycan structural features
Levels of glycans sharing the same structural features were
approximated by adding the structures having same characteris-
tics: Core fucosylated glycans (FUC-C) = DG6/(DG5+DG6)*100;
Antennary fucosylated glycans (FUC-A) = DG7/(DG5+DG7)*100.
Genotype and phenotype quality control
Genotyping quality control was performed using the same
procedures for all cohorts. Individuals with a call rate less than
97% were removed as well as SNPs with a call rate less than 98%
(95% for CROATIA-VIS), minor allele frequency less than 0.02%
or Hardy-Weinburg equilibrium p-value less than 1610
210.
Differences in SNP call rate threshold were used to account for
observed differences between genotyping arrays. 924 individuals
passed all quality control thresholds from CROATIA-VIS, 898
from CROATIA-KORCULA and 737 from ORCADES.
Extreme outliers were removed for each glycan measure to
account for errors in quantification and to remove individuals not
representative of normal variation within the population. An
individual was classified to be an extreme outlier if their measure
for the trait was more than 3 interquartile distances away from the
mean.
Genome-wide association analysis
Each trait was tested for normality within each cohort then the
transformation that performed best for all cohorts was used.
Models including sex, age and fibrinogen as covariates were tested
for each cohort separately. Any covariate that was significant
within any cohort was included as a covariate in the final model.
Genome-wide associations were performed for all glycan
measures using the same transformation to normality and
covariates for each cohort separately then combined in a meta-
analysis. The ‘‘mmscore’’ function of the GenABEL package for R
statistical software [53] was used for the association test under an
additive model. This score test for family based association takes
into account pedigree structure and allowed unbiased estimations
of SNP allelic effect when relatedness is present between
examinees [54]. The relationship matrix used in this analysis
was generated by the ‘‘ibs’’ function of GenABEL which used IBS
genotype sharing to determine the realised pairwise kinship
coefficient. Meta-analysis was performed using the MetABEL
package for R [53]. An association was considered statistically
significant at the genome-wide level if the p-value for an individual
SNP was less that 5610
28 (based on Bonferroni correction to
account for multiple testing). All identified SNPs that reached
significance or seemed to be suggestive of significance were
visualised using Haploview software [55].
Association interval
An associated interval for a region of interest was defined by
determining the HapMap SNPs in linkage disequilibrium of r
2
.0.5 with the most significantly associated SNP in the region
using the web-based program SNAP [56]. The bounds of the
associated interval were determined by the flanking HapMap
recombination hotspots.
Haplotype analysis
Haplotype analysis was performed on ‘‘unrelated’’ individuals in
each population separately to account for possible allele frequency
and haplotype differences between populations. Individuals were
considered to be unrelated with a kinship coefficient of less than
0.05 (first cousins once removed). This left 525 individuals in the
CROATIA-VIS cohort, 568 in CROATIA-KORCULA and 263
in ORCADES. An EM based algorithm was used to infer
haplotypes from genotypic data. The ‘‘scan.haplo’’ function of the
GenABEL package for R [53], which calls the ‘‘haplo.score.slide’’
function of the haplo.stats package for R [57], was used to test a
sliding window of 3- and 5-SNP haplotypes across the associated
interval. These results were compared to a single SNP model
across the same region obtained using the ‘‘qtscore’’ function of
the GenABEL package for R. A significant difference between
haplotype and single-SNP analysis was determined using the
Akaike information criterion [58].
ChIP identification of HNF binding sites in FUT genes
To establish whether HNF1a and HNF4a bind the regulatory
elements of the fucosylation genes, their genomic loci were
analysed using bioinformatics to identify HNF response elements.
Conserved elements between human and mouse genomes [39]
were analysed initially to delineate the binding sites of HNF1a and
HNF4a using the TRANSFAC database and the ECR browser
(http://ecrbrowser.dcode.org/). Primers for ChIP, reChIP and
real-time PCR are listed in Text S1.
RNA interference
Production of the RNA duplexes for RNA interference was
described in details earlier (Kittler et al., 2005). The target
sequences (see Text S1) against HNF1a and HNF4a were designed
using the siDESIGN Center (Dharmacon). The Trasnfection of
HepG2 and PANC1 cells was carried out as described by (Yu
et al., 2002).
Luciferase assays
The PCR products of ChIP primers (Sequences are detailed in
the Text S1) were cloned into pGEM-T easy vector (Promega) and
subcloned into pGL4 vectors (Promega) as described earlier (Essafi
et al., 2005). pGL4-luc constructs (100 ng) and internal control of
pRLTK (20 ng) renilla plasmid were transiently co-transfected
into HepG2 and PANC1 cells (10
5) using the calcium phosphate
co-precipitation. Cells were harvested 48 hr post-transfection for
luciferase reporter assay using the Dual-Luciferase reporter assay
system (Promega). The luciferase activity was normalized by Renilla
luciferase activity. All assays were performed in three separate
experiments done in triplicate.
ChIP
ChIP was carried out on HepG2 cells essentially as detailed
earlier (Essafi et al., 2005). The antibodies used were HNF1a (sc-
6547) and HNF4a (sc-6556) from Santa Cruz Biotechnology. The
corresponding control IgG antibodies were from Sigma-Aldrich.
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RNA isolation, cDNA synthesis and Real time PCR were
performed as described earlier (Birkenkamp et al., 2007). PCR
primer sequences are listed in Text S1.
Supporting Information
Figure S1 PANC1 cells were treated with RNAi against HNF1a
and HNF4a. The expression levels of the indicated genes were
analysed by real time SYBR Green PCR.
Found at: doi:10.1371/journal.pgen.1001256.s001 (0.28 MB TIF)
Figure S2 PANC1 cells were treated with RNAi against HNF1a
and HNF4a. The expression levels of the indicated genes were
analysed by real time SYBR Green PCR.
Found at: doi:10.1371/journal.pgen.1001256.s002 (0.41 MB TIF)
Figure S3 The clustering of FUT3, FUT5 and FUT6 on
chromosome 19. The position of primer pairs used for ChIP are
indicated at the bottom of the figure.
Found at: doi:10.1371/journal.pgen.1001256.s003 (0.39 MB TIF)
Table S1 (A) Main structures present in glycan groups for which
Genome-wide significant associations were found (SNPs in FUT8,
FUT6 and HNF1a genes). (B) Glycan structures present in different
HPLC peaks.
Found at: doi:10.1371/journal.pgen.1001256.s004 (0.10 MB
DOC)
Table S2 Desialylated glycan traits (DG1-13, FUC-A, FUC-C)
and their associations with FUT6, FUT8 and HNF1a SNPs
showing their effect sizes (Beta) in standard deviation units (with
standard errors) and p-values. The fucosylation status of each trait
is also shown.
Found at: doi:10.1371/journal.pgen.1001256.s005 (0.06 MB
DOC)
Text S1 Supplemental Materials and Methods.
Found at: doi:10.1371/journal.pgen.1001256.s006 (0.05 MB
DOC)
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